COVID-19 cases on the rise in 10 states


COVID-19 cases have increased over the past 14 days in 10 states and Washington, DC, with Kentucky seeing the largest increase.

Nationwide, COVID-19 cases have declined 12% in the past 14 days, according to HHS data collected by The New York Times. As the more contagious omicron subvariant BA.2 continues to spread, cases are increasing in 10 states and DC as of March 25.

Here are the 14-day changes for cases in each state reporting an increase, according to HHS data collected by The New York Times:

Kentucky: 110%

New York: 69%

Colorado: 28%

Massachusetts: 27%

Washington, DC: 20%

Delaware: 18%

Connecticut: 17%

Vermont: 17%

Texas: 10%

Rhode Island: 9%

New Jersey: 2%

The CDC’s latest variant proportion estimates show that the omicron BA.2 subvariant accounts for more than a third of COVID-19 cases nationwide and more than half of cases in the Northeast. Rhode Island has the highest proportion of BA.2 cases of any state, according to the latest ranking of states by subvariant prevalence.

“If we maintain our preparedness, an increase in cases need not be cause for alarm as it once was,” said Jeff Zients, White House COVID-19 response coordinator, during from a March 23 press briefing. “We know what tools we need to fight the virus. Unfortunately, due to congressional action, we may not have those tools readily available.”

President Joe Biden signed into law a $1.5 trillion bill on March 15 that funds the government through September. The legislation did not include COVID-19 funding that the White House had requested from Congress due to a partisan disagreement over the funding offset.

There is no clear path to approval of additional funding for COVID-19.

Lack of funding affects resources for COVID-19 testing and treatment. The Health Resources and Services Administration stopped accepting claims from providers for COVID-19 testing and treatment of uninsured people on March 22 due to a lack of sufficient funds. The federal government is also cutting shipments of monoclonal antibody treatments to states by 30%, and the US supply of these treatments could run out as early as May.


About Author

Comments are closed.